Panel Rejection Of Targanta’s Oritavancin Shows That MRSA Matters Most
Executive Summary
Unconvincing data in a subgroup of patients with methicillin-resistant Staphylococcus aureus was the deciding factor in an FDA panel's Nov. 19 vote against Targanta's oritavancin for complicated skin and skin structure infections